261 related articles for article (PubMed ID: 20037204)
21. Parallel overexpression of seven kallikrein genes in ovarian cancer.
Yousef GM; Polymeris ME; Yacoub GM; Scorilas A; Soosaipillai A; Popalis C; Fracchioli S; Katsaros D; Diamandis EP
Cancer Res; 2003 May; 63(9):2223-7. PubMed ID: 12727843
[TBL] [Abstract][Full Text] [Related]
22. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression.
Rangel LB; Sherman-Baust CA; Wernyj RP; Schwartz DR; Cho KR; Morin PJ
Oncogene; 2003 Oct; 22(46):7225-32. PubMed ID: 14562052
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer.
Feng B; Xu WB; Zheng MH; Ma JJ; Cai Q; Zhang Y; Ji J; Lu AG; Qu Y; Li JW; Wang ML; Hu WG; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2006 Oct; 21(10):1596-603. PubMed ID: 16928223
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
25. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Scorilas A; Borgoño CA; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
J Clin Oncol; 2004 Feb; 22(4):678-85. PubMed ID: 14966091
[TBL] [Abstract][Full Text] [Related]
26. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker.
Huddleston HG; Wong KK; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2005 Jan; 96(1):77-83. PubMed ID: 15589584
[TBL] [Abstract][Full Text] [Related]
27. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
Zheng Y; Katsaros D; Shan SJ; de la Longrais IR; Porpiglia M; Scorilas A; Kim NW; Wolfert RL; Simon I; Li L; Feng Z; Diamandis EP
Clin Cancer Res; 2007 Dec; 13(23):6984-92. PubMed ID: 18056174
[TBL] [Abstract][Full Text] [Related]
28. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
29. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Borgoño CA; Grass L; Soosaipillai A; Yousef GM; Petraki CD; Howarth DH; Fracchioli S; Katsaros D; Diamandis EP
Cancer Res; 2003 Dec; 63(24):9032-41. PubMed ID: 14695222
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer.
Talieri M; Mathioudaki K; Prezas P; Alexopoulou DK; Diamandis EP; Xynopoulos D; Ardavanis A; Arnogiannaki N; Scorilas A
Thromb Haemost; 2009 Apr; 101(4):741-7. PubMed ID: 19350120
[TBL] [Abstract][Full Text] [Related]
31. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer.
Kim YW; Bae SM; Kim IW; Liu HB; Bang HJ; Chaturvedi PK; Battogtokh G; Lim H; Ahn WS
Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.
Walker G; MacLeod K; Williams AR; Cameron DA; Smyth JF; Langdon SP
Clin Cancer Res; 2007 Mar; 13(5):1438-44. PubMed ID: 17332286
[TBL] [Abstract][Full Text] [Related]
33. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
34. Correlation between Heterogeneous Expression of Sialyltransferases and MUC16 in Ovarian Tumor Tissues.
Bouanene H; Sahrawi W; Mokni M; Fatma LB; Bouriga A; Limen HB; Khairi H; Ahmed SB; Miled A
Onkologie; 2011; 34(4):165-9. PubMed ID: 21447973
[TBL] [Abstract][Full Text] [Related]
35. Validation of serum biomarkers for detection of early-stage ovarian cancer.
Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
[TBL] [Abstract][Full Text] [Related]
36. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer.
Koh SC; Razvi K; Chan YH; Narasimhan K; Ilancheran A; Low JJ; Choolani M;
Arch Gynecol Obstet; 2011 Jul; 284(1):183-90. PubMed ID: 20680316
[TBL] [Abstract][Full Text] [Related]
37. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
38. Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels.
Chao A; Lee LY; Hsueh C; Lin CY; Tsai CL; Chao AS; Lin CT; Chou HH; Chang TC; Wang TH
Taiwan J Obstet Gynecol; 2013 Jun; 52(2):185-91. PubMed ID: 23915849
[TBL] [Abstract][Full Text] [Related]
39. Coordinately up-regulated genes in ovarian cancer.
Hough CD; Cho KR; Zonderman AB; Schwartz DR; Morin PJ
Cancer Res; 2001 May; 61(10):3869-76. PubMed ID: 11358798
[TBL] [Abstract][Full Text] [Related]
40. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
White NM; Mathews M; Yousef GM; Prizada A; Popadiuk C; Doré JJ
Br J Cancer; 2009 Oct; 101(7):1107-13. PubMed ID: 19707197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
